Audio Journal of Oncology Podcast
by Audio Medica News
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇻🇳VN · Science#156500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
150 to 900🎙 Daily cadence·50 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
500 to 3K🇻🇳100% - Active Followers
Loyal subscribers who consistently listen
150 to 900
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 20 epsHost
Recent guests
Recent episodes
Kevin Kalinsky MD; ASCO 2026: ASCENT-04 Study Finds Sacituzumab Govitecan plus Pembrolizumab Helps Patients with Previously Untreated Metastatic PD-L1 Positive Triple Negative Breast Cancer Live Longer Without Progression Beyond Subsequent Therapies
Jul 14, 2026
7m 54s
Wing-Lok Chan MBBS; 2026 ASCO: Patients with Advanced Cancer Using The SUPPORT+ Mobile Phone App With Nurse Supervision have Better Quality of Life and Fewer Hospitalizations
Jul 8, 2026
9m 23s
Ghassan K. Abou-Alfa MD PhD; ASCO 2026: Adding Doublet Immune Checkpoint Inhibition to Embolization with or without anti-Growth Factor TKI Therapy Extends Progression Free Survival in Patients with Hepatocellular Cancer
Jun 30, 2026
8m 54s
Jonathan W. Goldman MD and David R Spigel MD; ASCO 2026: Patients with RET Fusion Positive Early Stage Non-Small Cell Lung Cancer Benefit from Selpercatinib: LIBRETTO-432 Early Results
Jun 23, 2026
9m 39s
Mark A Dickson, ASCO 2026: Abemaciclib Brings Marked Increase in Progression Free Survival for Patients with Advanced Dedifferentiated Liposarcoma
Jun 15, 2026
7m 24s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/14/26 | oncologybreast cancer+5 | Kevin Kalinsky MD | sacituzumab govitecanpembrolizumab+3 | Chicago, USAAtlanta, USA | sacituzumab govitecanpembrolizumab+5 | — | 7m 54s | ||
| 7/8/26 | advanced cancermobile health+4 | Wing-Lok Chan MBBS | Department of Clinical OncologyThe University of Hong Kong | Hong KongUSA | SUPPORT+ appadvanced cancer+5 | — | 9m 23s | ||
| 6/30/26 | Hepatocellular CancerImmune Checkpoint Inhibition+4 | Ghassan K. Abou-Alfa MD PhD | tremelimumabdurvalumab+3 | Chicago, USA | Hepatocellular Cancerimmune checkpoint inhibitors+5 | — | 8m 54s | ||
| 6/23/26 | oncologylung cancer+4 | Jonathan W. Goldman MDDavid R Spigel MD | SelpercatinibASCO | Non-Small Cell Lung Cancer | RET FusionSelpercatinib+5 | — | 9m 39s | ||
| 6/15/26 | oncologyliposarcoma+3 | Mark A Dickson | AbemaciclibASCO | Advanced Dedifferentiated Liposarcoma | Abemaciclibprogression free survival+3 | — | 7m 24s | ||
| 6/11/26 | breast canceraxillary lymph node dissection+4 | Jana de Boniface MD PhD | Department of Surgery, Capio St. Göra | — | breast canceraxillary lymph node dissection+4 | — | 6m 34s | ||
| 6/9/26 | Ovarian CancerSurgery Timing+4 | Jean-Marc Classe, MD PhD | ASCOTiming of Surgery for Advanced Ovarian Cancer among Neoadjuvant and Adjuvant Chemotherapy Cycles | — | Ovarian CancerSurgery+5 | — | 9m 04s | ||
| 6/5/26 | breast cancerendocrine therapies+3 | Peter Schmid MD PhD | GiredestrantASCO+1 | — | Giredestrantendocrine therapies+4 | — | 8m 30s | ||
| 6/4/26 | immune checkpoint inhibitorsmyocarditis+3 | Hassan Mohammed Abushukair MD | Oklahoma University | — | immune checkpoint inhibitorsmyocarditis+3 | — | 10m 44s | ||
| 6/2/26 | oncologypancreatic cancer+4 | Eileen M O'Reilly MD | DaraxonrasibASCO | Pancreas Cancer | DaraxonrasibRAS G12+5 | — | 13m 29s | ||
| 5/6/26 | KRAS inhibitorslung cancer+3 | Jonathan Wesley Riess MD | zoldonrasibUniversity of California Davis Comprehensive Cancer Center | — | KRAS G12Dzoldonrasib+3 | — | 8m 06s | ||
| 4/30/26 | whole exome sequencingctDNA+4 | Marija Balic MD PhD | NSABP Foundation, Inc.UPMC Hillman Cancer Center+2 | San Diego, USA | whole exome sequencingctDNA+5 | — | 10m 30s | ||
| 4/28/26 | Ovarian CancerAntibody Drug Conjugate+4 | Tao Zhu MD | QLS5132Zhejiang Cancer Hospital+1 | — | Anti-Claudin 6Ovarian Cancer+6 | — | 4m 50s | ||
| 4/27/26 | oral cancerintralesional PD 1 blockade+3 | Moran Amit MD PhD | University of Texas MD Anderson Cancer Center | Houston, Texas USA | oral cancerPD 1 blockade+5 | — | 10m 14s | ||
| 4/24/26 | oncologylung cancer+4 | Byoung Chul Cho MD PhD | elisrasibYonsei Cancer Center+2 | Seoul, South KoreaSAN DIEGO, USA | KRAS G12Clung cancer+6 | — | 7m 58s | ||
| 4/23/26 | molecular glue degraderadvanced solid tumors+4 | Elena Garralda MD PhD | DKY709PDR001+5 | Barcelona, SpainSan Diego, USA | molecular glue degraderadvanced solid tumors+5 | — | 8m 38s | ||
| 4/16/26 | breast cancerendocrine therapy+4 | Icro Meattini MD | University of FlorenceAzienda Ospedaliero-Universitaria Careggi+1 | Barcelona, Spain | breast cancerendocrine therapy+6 | — | 5m 16s | ||
| 4/13/26 | axillary radiotherapybreast cancer+4 | Amparo Garcia-Tejedor MD, PhD | University of BarcelonaBellvitge University Hospital+1 | Barcelona, Spain | axillary radiotherapyaxillary lymphadenectomy+5 | — | 6m 33s | ||
| 4/6/26 | breast cancerradiation therapy+3 | Eline Verreck BSc | Erasmus University Medical CentreAudio Journal of Oncology | RotterdamBarcelona | radiation boostearly breast cancer+3 | — | 7m 01s | ||
| 4/3/26 | radiotherapybreast cancer+4 | Fleur Mauritz MD | MAASTRO Institute of Radiation Oncology and ResearchRAPCHEM Study | MaastrichtNetherlands+1 | radiotherapybreast cancer+5 | — | 6m 08s |
Showing 20 of 20
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for Audio Journal of Oncology Podcast
Peaked at #156 in VN, currently #156 in VN.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| VN | — | #156 | #156 | — |
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.